Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Weatherhead School’s J.B. Silvers answers questions about impact of Obamacare on amount of uninsured Americans
- Psychology’s Lisa Damour writes about false perception that girls are meaner than their male peers
- History professor’s Twitter account goes viral—again
- Give to “Shop with a Cop” fundraiser to help local families
- Learn how to help students navigate study abroad process at Dec. 3 Global Talk session